Qiagen (QGEN) Stock Forecast, Price Target & Predictions
QGEN Stock Forecast
Qiagen stock forecast is as follows: an average price target of $51.89 (represents a 26.59% upside from QGEN’s last price of $40.99) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
QGEN Price Target
The average price target for Qiagen (QGEN) is $51.89 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $58.00 to $46.00. This represents a potential 26.59% upside from QGEN's last price of $40.99.
QGEN Analyst Ratings
According to 6 Wall Street analysts, Qiagen's rating consensus is 'Buy'. The analyst rating breakdown for QGEN stock is 0 'Strong Buy' (0.00%), 4 'Buy' (66.67%), 2 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Qiagen Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 17, 2024 | Shubhangi Gupt | HSBC | $49.00 | $43.21 | 13.40% | 19.54% |
| Jun 27, 2024 | Doug Schenkel | Wolfe Research | $50.00 | $41.21 | 21.33% | 21.98% |
| Jun 18, 2024 | John Sourbeer | UBS | $46.00 | $43.75 | 5.14% | 12.22% |
| Nov 04, 2021 | Daniel Brennan | Cowen & Co. | $58.00 | $55.64 | 4.24% | 41.50% |
| Jul 15, 2021 | Derik De Bruin | Bank of America Securities | $52.00 | $47.92 | 8.51% | 26.86% |
| Jul 14, 2021 | Patrick B Donnelly | Citigroup | $58.00 | $46.55 | 24.60% | 41.50% |
| Jul 13, 2021 | Ulrich Huwald | Warburg Research | $50.25 | $47.14 | 6.59% | 22.58% |
The latest Qiagen stock forecast, released on Oct 17, 2024 by Shubhangi Gupt from HSBC, set a price target of $49.00, which represents a 13.40% increase from the stock price at the time of the forecast ($43.21), and a 19.54% increase from QGEN last price ($40.99).
Qiagen Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $49.00 | $48.33 |
| Last Closing Price | $40.99 | $40.99 | $40.99 |
| Upside/Downside | -100.00% | 19.54% | 17.91% |
In the current month, the average price target of Qiagen stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Qiagen's last price of $40.99. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 17, 2024 | HSBC | - | Hold | Downgrade |
| Aug 05, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Jun 27, 2024 | Wolfe Research | - | Outperform | Upgrade |
| Jun 18, 2024 | UBS | Neutral | Neutral | Hold |
| Jun 17, 2024 | Citigroup | Buy | Buy | Hold |
| Feb 16, 2024 | Morgan Stanley | - | Overweight | Upgrade |
| Dec 07, 2023 | Goldman Sachs | - | Buy | Upgrade |
Qiagen's last stock rating was published by HSBC on Oct 17, 2024. The company Downgrade its QGEN rating from "null" to "Hold".
Qiagen Financial Forecast
Qiagen Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $485.40M | $497.98M | $499.63M | $515.51M | $628.39M | $582.40M | $534.75M | $567.31M | $567.21M | $571.23M | $483.76M | $443.25M | $372.10M | $413.47M | $382.69M |
| Avg Forecast | $559.23M | $535.63M | $531.49M | $488.23M | $543.46M | $525.05M | $520.60M | $480.25M | $520.85M | $491.20M | $495.45M | $453.91M | $500.77M | $469.79M | $492.21M | $480.55M | $489.92M | $483.01M | $504.55M | $589.78M | $531.21M | $497.50M | $564.01M | $557.27M | $548.27M | $464.55M | $433.92M | $344.66M | $408.67M | $383.01M |
| High Forecast | $565.52M | $541.65M | $537.47M | $493.71M | $549.57M | $530.95M | $526.45M | $484.69M | $524.87M | $491.82M | $495.46M | $453.91M | $511.24M | $476.37M | $497.74M | $485.95M | $495.42M | $483.01M | $504.55M | $589.78M | $531.21M | $497.50M | $564.01M | $557.27M | $548.27M | $464.55M | $433.92M | $344.66M | $408.67M | $383.01M |
| Low Forecast | $554.15M | $530.77M | $526.67M | $483.79M | $538.53M | $520.28M | $515.87M | $477.50M | $519.23M | $490.58M | $495.45M | $453.91M | $491.53M | $464.47M | $487.74M | $476.19M | $485.47M | $483.01M | $504.55M | $589.78M | $531.21M | $497.50M | $564.01M | $557.27M | $548.27M | $464.55M | $433.92M | $344.66M | $408.67M | $383.01M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 5 | 8 | 4 | 3 | 3 | 6 | 9 | 7 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 7 | 7 | 9 | 8 | 6 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 1.02% | 1.03% | 1.02% | 1.07% | 1.10% | 1.07% | 1.01% | 1.02% | 1.04% | 1.04% | 1.02% | 1.08% | 1.01% | 1.00% |
Qiagen's average Quarter revenue forecast for Jun 23 based on 7 analysts is $492.21M, with a low forecast of $487.74M, and a high forecast of $497.74M. QGEN's average Quarter revenue forecast represents a 1.40% increase compared to the company's last Quarter revenue of $485.40M (Mar 23).
Qiagen EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 5 | 8 | 4 | 3 | 3 | 6 | 9 | 7 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 7 | 7 | 9 | 8 | 6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $181.11M | $134.73M | $188.54M | $184.34M | $268.04M | $228.94M | $219.19M | $218.89M | $228.22M | $330.56M | $96.78M | $174.73M | $113.73M | $140.22M | $-152.88M |
| Avg Forecast | $181.70M | $174.03M | $172.69M | $158.63M | $176.58M | $170.59M | $169.15M | $156.04M | $169.23M | $159.59M | $160.98M | $286.68M | $162.70M | $152.64M | $159.92M | $260.62M | $193.07M | $184.19M | $192.40M | $236.93M | $202.56M | $189.71M | $215.07M | $217.36M | $209.07M | $177.15M | $165.46M | $84.24M | $155.84M | $146.05M |
| High Forecast | $183.74M | $175.99M | $174.63M | $160.41M | $178.56M | $172.51M | $171.05M | $157.48M | $170.53M | $159.80M | $160.98M | $344.02M | $166.11M | $154.78M | $161.72M | $312.74M | $231.68M | $184.19M | $192.40M | $284.31M | $202.56M | $189.71M | $215.07M | $260.83M | $209.07M | $177.15M | $165.46M | $101.09M | $155.84M | $146.05M |
| Low Forecast | $180.05M | $172.45M | $171.12M | $157.19M | $174.97M | $169.05M | $167.61M | $155.14M | $168.70M | $159.39M | $160.98M | $229.35M | $159.70M | $150.91M | $158.47M | $208.50M | $154.46M | $184.19M | $192.40M | $189.54M | $202.56M | $189.71M | $215.07M | $173.89M | $209.07M | $177.15M | $165.46M | $67.39M | $155.84M | $146.05M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.69% | 0.70% | 1.02% | 0.96% | 1.13% | 1.13% | 1.16% | 1.02% | 1.05% | 1.58% | 0.55% | 1.06% | 1.35% | 0.90% | -1.05% |
7 analysts predict QGEN's average Quarter EBITDA for Jun 23 to be $159.92M, with a high of $161.72M and a low of $158.47M. This is -11.70% lower than Qiagen's previous annual EBITDA (Mar 23) of $181.11M.
Qiagen Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 5 | 8 | 4 | 3 | 3 | 6 | 9 | 7 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 7 | 7 | 9 | 8 | 6 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $85.03M | $88.84M | $82.39M | $96.66M | $155.31M | $129.19M | $133.14M | $121.05M | $129.22M | $212.69M | $16.91M | $89.76M | $39.83M | $44.93M | $-160.63M |
| Avg Forecast | $152.99M | $139.18M | $137.62M | $114.45M | $140.94M | $131.09M | $126.97M | $108.88M | $134.93M | $121.72M | $116.62M | $169.91M | $123.45M | $111.09M | $115.92M | $154.46M | $108.95M | $103.25M | $104.50M | $140.42M | $138.78M | $122.58M | $149.71M | $123.07M | $147.91M | $129.26M | $110.68M | $29.50M | $100.91M | $79.88M |
| High Forecast | $155.22M | $141.21M | $139.63M | $116.12M | $143.00M | $133.01M | $128.83M | $110.47M | $137.17M | $122.02M | $116.90M | $203.89M | $125.65M | $113.41M | $117.61M | $185.35M | $130.74M | $103.25M | $104.50M | $168.50M | $138.78M | $122.58M | $149.71M | $147.68M | $147.91M | $129.26M | $110.68M | $35.40M | $100.91M | $79.88M |
| Low Forecast | $151.18M | $137.53M | $135.99M | $113.10M | $139.27M | $129.55M | $125.47M | $104.52M | $132.68M | $121.42M | $116.33M | $135.93M | $121.24M | $108.78M | $114.55M | $123.57M | $87.16M | $103.25M | $104.50M | $112.34M | $138.78M | $122.58M | $149.71M | $98.46M | $147.91M | $129.26M | $110.68M | $23.60M | $100.91M | $79.88M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.55% | 0.82% | 0.80% | 0.92% | 1.11% | 0.93% | 1.09% | 0.81% | 1.05% | 1.44% | 0.13% | 0.81% | 1.35% | 0.45% | -2.01% |
Qiagen's average Quarter net income forecast for Jun 23 is $115.92M, with a range of $114.55M to $117.61M. QGEN's average Quarter net income forecast represents a 36.32% increase compared to the company's last Quarter net income of $85.03M (Mar 23).
Qiagen SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 5 | 8 | 4 | 3 | 3 | 6 | 9 | 7 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 7 | 7 | 9 | 8 | 6 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $147.58M | $154.21M | $145.46M | $151.42M | $152.85M | $152.27M | $143.22M | $141.41M | $147.56M | $153.07M | $130.10M | $118.24M | $123.95M | $123.60M | $125.77M |
| Avg Forecast | $163.03M | $156.15M | $154.94M | $142.33M | $158.43M | $153.06M | $151.77M | $140.00M | $151.84M | $143.19M | $144.43M | $167.22M | $145.98M | $136.95M | $143.49M | $152.02M | $128.42M | $140.81M | $147.09M | $138.20M | $154.86M | $145.03M | $164.42M | $140.54M | $159.83M | $135.43M | $126.50M | $91.82M | $119.13M | $111.65M |
| High Forecast | $164.86M | $157.90M | $156.68M | $143.93M | $160.21M | $154.78M | $153.47M | $141.30M | $153.01M | $143.37M | $144.44M | $200.66M | $149.04M | $138.87M | $145.10M | $182.42M | $154.10M | $140.81M | $147.09M | $165.84M | $154.86M | $145.03M | $164.42M | $168.64M | $159.83M | $135.43M | $126.50M | $110.18M | $119.13M | $111.65M |
| Low Forecast | $161.55M | $154.73M | $153.53M | $141.04M | $156.99M | $151.67M | $150.39M | $139.20M | $151.37M | $143.01M | $144.43M | $133.77M | $143.29M | $135.40M | $142.19M | $121.61M | $102.73M | $140.81M | $147.09M | $110.56M | $154.86M | $145.03M | $164.42M | $112.43M | $159.83M | $135.43M | $126.50M | $73.45M | $119.13M | $111.65M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.97% | 1.20% | 1.03% | 1.03% | 1.11% | 0.98% | 0.99% | 0.86% | 1.05% | 0.96% | 0.96% | 0.93% | 1.35% | 1.04% | 1.13% |
Qiagen's average Quarter SG&A projection for Jun 23 is $143.49M, based on 7 Wall Street analysts, with a range of $142.19M to $145.10M. The forecast indicates a -2.77% fall compared to QGEN last annual SG&A of $147.58M (Mar 23).
Qiagen EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 5 | 8 | 4 | 3 | 3 | 6 | 9 | 7 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 7 | 7 | 9 | 8 | 6 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.37 | $0.39 | $0.36 | $0.42 | $0.68 | $0.57 | $0.58 | $0.53 | $0.57 | $0.93 | $0.07 | $0.39 | $0.17 | $0.20 | $-0.71 |
| Avg Forecast | $0.68 | $0.62 | $0.61 | $0.51 | $0.63 | $0.59 | $0.57 | $0.49 | $0.60 | $0.54 | $0.52 | $0.44 | $0.55 | $0.50 | $0.52 | $0.48 | $0.48 | $0.47 | $0.47 | $0.74 | $0.63 | $0.55 | $0.67 | $0.65 | $0.67 | $0.58 | $0.50 | $0.28 | $0.45 | $0.36 |
| High Forecast | $0.69 | $0.63 | $0.62 | $0.52 | $0.64 | $0.59 | $0.58 | $0.49 | $0.61 | $0.54 | $0.52 | $0.44 | $0.56 | $0.51 | $0.52 | $0.49 | $0.49 | $0.47 | $0.47 | $0.74 | $0.63 | $0.55 | $0.67 | $0.65 | $0.67 | $0.58 | $0.50 | $0.28 | $0.45 | $0.36 |
| Low Forecast | $0.67 | $0.61 | $0.61 | $0.50 | $0.62 | $0.58 | $0.56 | $0.47 | $0.59 | $0.54 | $0.52 | $0.44 | $0.54 | $0.49 | $0.51 | $0.47 | $0.48 | $0.47 | $0.47 | $0.74 | $0.63 | $0.55 | $0.67 | $0.65 | $0.67 | $0.58 | $0.50 | $0.28 | $0.45 | $0.36 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.77% | 0.81% | 0.77% | 0.89% | 0.92% | 0.91% | 1.05% | 0.79% | 0.88% | 1.40% | 0.12% | 0.78% | 0.61% | 0.43% | -1.97% |
According to 7 Wall Street analysts, Qiagen's projected average Quarter EPS for Jun 23 is $0.52, with a low estimate of $0.51 and a high estimate of $0.52. This represents a 39.84% increase compared to QGEN previous annual EPS of $0.37 (Mar 23).
Qiagen Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AKU | Akumin | $0.29 | $3.00 | 934.48% | - |
| ACRS | Aclaris Therapeutics | $3.14 | $14.00 | 345.86% | Buy |
| GTH | Genetron | $4.03 | $10.00 | 148.14% | - |
| GH | Guardant Health | $28.96 | $57.27 | 97.76% | Buy |
| ICLR | ICON Public Limited Company | $187.22 | $309.60 | 65.37% | Buy |
| NEO | NeoGenomics | $15.01 | $23.00 | 53.23% | Buy |
| IQV | IQVIA | $191.04 | $266.65 | 39.58% | Buy |
| MEDP | Medpace | $308.93 | $399.20 | 29.22% | Hold |
| QGEN | Qiagen | $40.99 | $51.89 | 26.59% | Buy |
| SHC | Sotera Health Company | $13.88 | $17.43 | 25.58% | Buy |
| NEOG | Neogen | $15.20 | $17.50 | 15.13% | Buy |
| OLK | Olink AB (publ) | $26.08 | $21.50 | -17.56% | Hold |
| NTRA | Natera | $153.42 | $120.92 | -21.18% | Buy |